Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 10, 2008
- GS1 Healthcare Tokyo Conference Calls For Use of GS1 Codes
November 10, 2008
- Lenalidomide Shows Teratogenicity: Celgene
November 10, 2008
- Daiichi Sankyo: Increases in Number of MRs in the US, Europe Impact on Profits
November 10, 2008
- R&D NEWS IN BRIEF
November 10, 2008
- Eisai: Aricept, MGI Pharma's Products Push Up Sales 9.9%
November 10, 2008
- JSMI Adds 20 APIs as Candidates for Switch OTC Drugs
November 10, 2008
- MTPC: Sales Down 0.7% Despite Strong Growth of Remicade, Mearubik
November 10, 2008
- Taisho: Strong Self-med. Business Makes Up for Slump of Ethical Drugs Business
November 10, 2008
- DSP: New Products Make Up for Decreases in Sales of Amlodin
November 10, 2008
- SSP: Sales Remain Soft but Profits Jump
November 10, 2008
- OPINION／Passion and Principles: Keys to Unlocking Talent
November 3, 2008
- ASKA Obtains Approval for Menoaid Combipatch
November 3, 2008
- Korosho to Review Opinions Received on Online Sale of OTC Drugs
November 3, 2008
- Daiichi Sankyo Responds to Speculation on Status of Prasugrel NDA
November 3, 2008
- Olympus Launches Endo Capsule
November 3, 2008
- PMDA to Increase Staff with Academic Background in Natural Sciences
November 3, 2008
- Korosho to Optimize Approved Doses for 4 Thiazide Diuretics
November 3, 2008
- NEW PRODUCTS
November 3, 2008
- Irribow Drug of Choice for Diarrhea-Predominant IBS
November 3, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…